iα52

Iα52 is a naturally occurring peptide derived from the murine I-Eα chain, specifically from residues 52 to 68. It is involved in the selection process of immature T cells.

Iα52 acetate(137756-45-7 free base) 是一种天然加工的肽，包含鼠 I-Eα 链的 52-68 位残基，可能有助于选择未成熟的 T 细胞。

EEDi-5285 是一种非常有效且具有口服活性的胚胎外胚层发育 (EED) 抑制剂，结合 EED 蛋白的 IC50 值为 0.2 nM，并具有抗癌活性。

PKI (5-24) Acetate(99534-03-9 free base) 是一种高亲和力 PKA 抑制剂 (Ki = 2.3 nM)。

GYKI 52466 dihydrochloride (GYKI 52466 2HCl) 是一种具有良好的血脑屏障通透性、口服活性和选择性的 AMPA Kainate 受体拮抗剂，具有抗惊厥活性，可用于研究帕金森和癫痫等神经系统疾病。

GYKI-52466 is a selective non-competitive AMPA receptor antagonist (IC50 values are 10-20, ~ 450 and >50 μM for AMPA-, kainate- and NMDA-induced responses, respectively) used as a Skeletal muscle relaxant, orally active anticonvulsant, neuroprotective and

EEDi-5285 TFA（2488952-40-3 Free base） is a potent and orally active small molecule inhibitor of embryonic ectodermal development (EED) with an IC50 value of 0.2 nM and excellent pharmacokinetics.

PKSI-527 is an inhibitor of plasma kallikrein (Ki = 0.81 μM). It is selective for plasma kallikrein over glandular kallikrein, plasmin, thrombin, urokinase, and Factor Xa (Kis = >500, 390, >500, 200, and >500 μM, respectively). PKSI-527 reduces bradykinin generation induced by kaolin and λ-carrageenan ex vivo in human plasma. It also prolongs partial thromboplastin and euglobulin clot lysis times. In vivo, PKSI-527 (300 mg/kg per day) reduces hyperplasia, pannus formation, and infiltration of inflammatory cells in the tarsal joint of mice with collagen-induced arthritis.

EEDi-5273 is a highly potent and orally efficacious inhibitor of EED, with an approximate IC50 value of 0.2 nM. This compound exhibits exceptional activity, capable of achieving complete and persistent regression of tumors.

Osteoprotegerin is a soluble secreted member of the tumor necrosis factor receptor superfamily, inhibiting osteoclastogenesis by interrupting the signaling between stromal cells and osteoclastic progenitor cells, leading to excess accumulation of bone and cartilage.

GYKI 52466 is an allosteric AMPA receptor antagonist. It selectively inhibits AMPA-induced inward currents (IC50 = 7.5 µM) over NMDA- or GABA-induced inward currents in primary rat hippocampal neurons at 50 µM but also inhibits kainate-induced inward currents in the same cells (IC50 = 11 µM).2 GYKI 52466 (10 µM) reduces the amplitude of spontaneous excitatory postsynaptic currents (EPSCs) in the same cells. It increases the latency to seizure onset and reduces mortality in a rat model of generalized tonic-clonic seizures induced by 4-aminopyridine (4-AP) when administered at doses of 25 and 50 mg kg. GYKI 52466 (30 mg kg) prevents neuronal damage in the CA1 region of the hippocampus in a rat model of global ischemia-reperfusion injury induced by four-vessel occlusion.

PKI(5-24) TFA 是一种强效、竞争性、合成的PKA(cAMP 依赖性蛋白激酶) 抑制剂，Ki 为 2.3 nM。PKI(5-24) TFA 对应于天然存在的热稳定蛋白激酶抑制剂中的 5-24 残基。

PKI(5-22)amide 是环 AMP 依赖性蛋白激酶 (PKA) 抑制剂的活性片段。PKI(5-22)amide 抑制PKA 激活，但不能减弱 CRF1 受体的同源脱敏作用。

PKI (5-24),amide (IP20-amide)为对应于cAMP依赖性蛋白激酶热稳定抑制蛋白活性部分的20残基肽。该化合物是一种高效的cAMP依赖性蛋白激酶(PKA)抑制剂，具有2.3 nM的Ki值。

Enokizumab (MEDI-528) 是一种针对白介素 IL-9 的单克隆抗体。Enokizumab 可用于研究哮喘疾病。

Motavizumab (MEDI-524) 是一种中和抗呼吸道合胞病毒 （Rsv) 单克隆抗体，可改变小鼠模型中 Rsv 诱导的局部和全身细胞因子反应，可用于研究呼吸道合胞病毒感染。

Etaracizumab (LM 609) 是一种靶向整合素 αvβ3 的人源化单克隆抗体，抑制血管生成和黑色素瘤生长，可用于研究黑色素瘤。

NPI52 (Compound E1) 是一种专门抑制口蹄疫病毒 3C 蛋白酶 (FMDV 3Cpro) 的抑制剂，其在 FRET 和细胞检测中的IC50值分别为 0.05 µM 和 0.11 µM。

RIBI-529 (RC-529) 是一种脂质 A 模拟物 (氨基烷基氨基葡糖 4-磷酸盐)，其佐剂效用与 MPL (Corixa) 相似。RIBI-529 通过激活 Toll 样受体 4 发出信号以刺激先天免疫系统。

High affinity PKA inhibitor (Ki = 2.3 nM).